Published August 31, 2026 | Version v1

The Ghost Genome: Mapping a Constrained Chemical Execution Layer of Human Biology

  • 1. Biosortia

Description

Genomics maps biological capacity but does not directly report the real-time chemistry produced when 
host and microbial genes, viruses, diet, medicines, anatomy, environment, and time interact. Here, the 
ghost genome is a temporary working name for the unknown or under-characterized portion of this 
chemical execution layer—not a second chromosome. A ghost is an unresolved trace: once identity, 
exposure, function, and causality are adequately established, the label should be retired and the 
evidence made available to other laboratories and provenance-rich models. At a particular site and 
moment, realized chemistry is constrained by substrates, expression, ecological interactions, 
geography, transport, and clearance, although the cumulative repertoire across populations and contexts 
may be large. This perspective separates established host–microbial co-metabolism from hypotheses 
about distributed assembly, biologically realized priors, discovery productivity, and nature-like 
polypharmacology by design. The near-term requirement is an observatory that preserves who 
contributed the chemistry, where and when it appeared, and how matter was transformed. For global 
health, that observatory must include representative populations and local ecologies, use common 
confidence standards, and connect unresolved activity to causal chemistry, sustainable manufacture, 
delivery, and public trust. 

Files

The Ghost Genome Mapping a Constrained Chemical Execution Layer.pdf

Files (331.9 kB)

Additional details

Related works

Is supplement to
Book: 979-8--99736052-8 (ISBN)
Book: 979-8--99736054-2 (ISBN)
Book: 979-8--99736050-4 (ISBN)

Dates

Submitted
2026-08-31
Perspective

References

  • National Human Genome Research Institute. Gene Sweepstakes (GeneSweep). Updated November 26, 2024. Accessed August 28, 2026. https://www.genome.gov/virtual-exhibits/GeneSweep
  • International Human Genome Sequencing Consortium. Finishing the euchromatic sequence of the human genome. Nature. 2004;431(7011):931-945. doi:10.1038/nature03001
  • Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature. 2012;486(7402):207-214. doi:10.1038/nature11234
  • Nicholson JK, Holmes E, Kinross J, et al. Host-gut microbiota metabolic interactions. Science. 2012;336(6086):1262-1267. doi:10.1126/science.1223813
  • Donia MS, Fischbach MA. Small molecules from the human microbiota. Science. 2015;349(6246):1254766. doi:10.1126/science.1254766
  • da Silva RR, Dorrestein PC, Quinn RA. Illuminating the dark matter in metabolomics. Proc Natl Acad Sci U S A. 2015;112(41):12549-12550. doi:10.1073/pnas.1516878112
  • Dodd D, Spitzer MH, Van Treuren W, et al. A gut bacterial pathway metabolizes aromatic amino acids into nine circulating metabolites. Nature. 2017;551(7682):648-652. doi:10.1038/nature24661
  • Koppel N, Rekdal VM, Balskus EP. Chemical transformation of xenobiotics by the human gut microbiota. Science. 2017;356(6344):eaag2770. doi:10.1126/science.aag2770
  • Youngs RO. The Ghost Genome: The Hidden Chemical Language Inside Us—and Why Medicine Has Barely Begun to Read It. 1st ed. Breaking Life Sciences; 2026. ISBN 979-8-9973605-2-8. LCCN 2026920922.
  • Newman DJ, Cragg GM. Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. J Nat Prod. 2020;83(3):770-803. doi:10.1021/acs.jnatprod.9b01285
  • Atanasov AG, Zotchev SB, Dirsch VM, et al. Natural products in drug discovery: advances and opportunities. Nat Rev Drug Discov. 2021;20(3):200-216. doi:10.1038/s41573-020-00114-z
  • Cohen LJ, Esterhazy D, Kim SH, et al. Commensal bacteria make GPCR ligands that mimic human signalling molecules. Nature. 2017;549(7670):48-53. doi:10.1038/nature23874
  • Kruger R, Oler E, Saha S, et al. MiMeDB 2.0: the Human Microbial Metabolome Database for 2026. Nucleic Acids Res. 2026;54(D1):D623-D634. doi:10.1093/nar/gkaf1272
  • Campbell WC, Fisher MH, Stapley EO, Albers-Schönberg G, Jacob TA. Ivermectin: a potent new antiparasitic agent. Science. 1983;221(4613):823-828. doi:10.1126/science.6308762
  • Omura S, Crump A. The life and times of ivermectin: a success story. Nat Rev Microbiol. 2004;2(12):984-989. doi:10.1038/nrmicro1048
  • Wang M, Carver JJ, Phelan VV, et al. Sharing and community curation of mass spectrometry data with Global Natural Products Social Molecular Networking. Nat Biotechnol. 2016;34(8):828-837. doi:10.1038/nbt.3597
  • Scannell JW, Blanckley A, Boldon H, Warrington B. Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov. 2012;11(3):191-200. doi:10.1038/nrd3681
  • Jumper J, Evans R, Pritzel A, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596(7873):583-589. doi:10.1038/s41586-021-03819-2
  • Abramson J, Adler J, Dunger J, et al. Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature. 2024;630(8016):493-500. doi:10.1038/s41586-024-07487-w
  • Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol. 2008;4(11):682-690. doi:10.1038/nchembio.118
  • Anighoro A, Bajorath J, Rastelli G. Polypharmacology: challenges and opportunities in drug discovery. J Med Chem. 2014;57(19):7874-7887. doi:10.1021/jm5006463